Mission
The mission of the HESI Immunotoxicology Technical Committee (ITC) is to identify and address scientific issues related to the development and application of immunotoxicology to public health and human health risk assessment; promote the understanding and appropriate use of immunotoxicologic data to protect human health; and contribute substantively to the scientific decision making processes relative to the development of guidelines and regulations for immunotoxicologic testing at the local, national, and international levels.
|
 Committee Factsheet
Committee Publications
Committee Events
Committee Presentations and Data Resources
|
Committee Participation
2010 Government and Academic Participants
Centre Antipoison-Centre de Pharmacovigilance (France)
Medical College of Virginia/Virginia
Commonwealth University
US Food and Drug Administration
Center for Drug Evaluation and Research
University of Aachen (Germany)
Utrecht University (The Netherlands)
2010 Committee Membership
Abbott Laboratories
Amgen, Inc.
AstraZeneca AB
Bayer AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Charles River Laboratories
The Dow Chemical Company
Eli Lilly and Company
F. Hoffmann-La Roche Inc.
GlaxoSmithKline
Johnson & Johnson Pharmaceuticals
Merck & Co., Inc.
Novartis Pharmaceuticals Corporation
Pfizer Inc.
sanofi-aventis
|
|
Contact:
Chair:
Ellen Evans, PhD
Schering-Plough Research Institute
Vice Chair:
Thomas Kawabata, PhD
Pfizer Global Research and Development
HESI Staff:
Dr. Raegan O'Lone, rolone@hesiglobal.org
Mr. Eric Moore
(202) 659-3306
|
